Lena E Friberg

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 48

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacokinetics

Clinical pharmacology and therapeutics

The Journal of antimicrobial chemotherapy

Uppsala Universitet

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Uppsala Universitet Dec 01 2014

Sweden

Professor :: Pharmaceutical Biosciences

Publications

Vincent Aranzana-Climent, Wisse Van Os, Amir Nutman, Jonathan Lellouche, Yael Dishon-Benattar, Nadya Rakovitsky, George L Daikos, Anna Skiada, Ioannis Pavleas, Emanuele Durante-Mangoni, Ursula Theuretzbacher, Mical Paul, Yehuda Carmeli, Lena E Friberg
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes. Clinical and translational science 17 (7) (2024)
Anders Thorsted, Chiara Zecchin, Alienor Berges, Mats O Karlson, Lena E Friberg
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. Clinical pharmacology and therapeutics 116 (3) (2024)
Maddalena Centanni, Omar Zaher, David Elhad, Mats O Karlsson, Lena E Friberg
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Cancer chemotherapy and pharmacology (2024)
Vincent Aranzana-Climent, Wisse Van Os, Amir Nutman, Jonathan Lellouche, Yael Dishon-Benattar, Nadya Rakovitsky, George L Daikos, Anna Skiada, Ioannis Pavleas, Emanuele Durante-Mangoni, Ursula Theuretzbacher, Mical Paul, Yehuda Carmeli, Lena E Friberg
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes. Clinical and translational science 17 (7) (2024)
Vincent Aranzana-Climent, Wisse Van Os, Amir Nutman, Jonathan Lellouche, Yael Dishon-Benattar, Nadya Rakovitsky, George L Daikos, Anna Skiada, Ioannis Pavleas, Emanuele Durante-Mangoni, Ursula Theuretzbacher, Mical Paul, Yehuda Carmeli, Lena E Friberg
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes. Clinical and translational science 17 (7) (2024)
Anders Thorsted, Chiara Zecchin, Alienor Berges, Mats O Karlson, Lena E Friberg
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. Clinical pharmacology and therapeutics (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology (2024)
Maddalena Centanni, Niels Reijnhout, Abel Thijs, Mats O Karlsson, Lena E Friberg
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework. Clinical pharmacokinetics 63 (6) (2024)
Anna Olsson, Christer Malmberg, Chenyan Zhao, Lena E Friberg, Elisabet I Nielsen, Pernilla Lagerbäck, Thomas Tängdén
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: agreement with in silico predictions. The Journal of antimicrobial chemotherapy 79 (2) (2024)
Anna Olsson, Christer Malmberg, Chenyan Zhao, Lena E Friberg, Elisabet I Nielsen, Pernilla Lagerbäck, Thomas Tängdén
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: agreement with in silico predictions. The Journal of antimicrobial chemotherapy 79 (2) (2024)
Maddalena Centanni, Niels Reijnhout, Abel Thijs, Mats O Karlsson, Lena E Friberg
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework. Clinical pharmacokinetics 63 (6) (2024)
Maddalena Centanni, Niels Reijnhout, Abel Thijs, Mats O Karlsson, Lena E Friberg
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework. Clinical pharmacokinetics (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Maddalena Centanni, Niels Reijnhout, Abel Thijs, Mats O Karlsson, Lena E Friberg
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework. Clinical pharmacokinetics 63 (6) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anna Olsson, Christer Malmberg, Chenyan Zhao, Lena E Friberg, Elisabet I Nielsen, Pernilla Lagerbäck, Thomas Tängdén
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: agreement with in silico predictions. The Journal of antimicrobial chemotherapy 79 (2) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Javier Sánchez, Christina Claus, Rosmarie Albrecht, Brenda C Gaillard, Joana Marinho, Christine McIntyre, Tamara Tanos, Axel Boehnke, Lena E Friberg, Siv Jonsson, Nicolas Frances
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology. CPT: pharmacometrics & systems pharmacology (2023)
Han Liu, Ana-Marija Milenković-Grišić, Sreenath M Krishnan, Siv Jonsson, Lena E Friberg, Pascal Girard, Karthik Venkatakrishnan, Yulia Vugmeyster, Akash Khandelwal, Mats O Karlson
A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer. CPT: pharmacometrics & systems pharmacology (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics 113 (4) (2023)
Eman I K Ibrahim, Mats O Karlson, Lena E Friberg
Assessment of Ibrutinib Scheduling on Leukocyte, Lymph Node Size and Blood Pressure Dynamics in Chronic Lymphocytic Leukemia through Pharmacokinetic-Pharmacodynamic Models. CPT: pharmacometrics & systems pharmacology (2023)
Maddalena Centanni, Mirjam E van de Velde, Aniek Uittenboogaard, Gertjan J L Kaspers, Mats O Karlsson, Lena E Friberg
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clinical pharmacokinetics 63 (2) (2023)
Anna Olsson, Christer Malmberg, Chenyan Zhao, Lena E Friberg, Elisabet I Nielsen, Pernilla Lagerbäck, Thomas Tängdén
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: agreement with in silico predictions. The Journal of antimicrobial chemotherapy (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical pharmacology and therapeutics (2023)
Anders Thorsted, Anh Duc Pham, Lena E Friberg, Elisabet I Nielsen
Model-based assessment of neutrophil-mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies. CPT: pharmacometrics & systems pharmacology (2023)
Yaru Peng, Iris K Minichmayr, Han Liu, Feifan Xie, Lena E Friberg
Multistate modeling for survival analysis in critically ill patients treated with meropenem. CPT: pharmacometrics & systems pharmacology (2023)
Maddalena Centanni, Mirjam E van de Velde, Aniek Uittenboogaard, Gertjan J L Kaspers, Mats O Karlsson, Lena E Friberg
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clinical pharmacokinetics 63 (2) (2023)
Maddalena Centanni, Mirjam E van de Velde, Aniek Uittenboogaard, Gertjan J L Kaspers, Mats O Karlsson, Lena E Friberg
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clinical pharmacokinetics (2023)
Sreenath M Krishnan, Lena E Friberg, Francois Mercier, Rong Zhang, Benjamin Wu, Jin Yan Jin, Tien Hoang, Marcus Ballinger, René Bruno, Mats O Karlson
Multistate pharmacometric model to define the impact of second-line immuno-therapies on the survival outcome of IMpower131 study. Clinical pharmacology and therapeutics (2023)
Maddalena Centanni, Mirjam E van de Velde, Aniek Uittenboogaard, Gertjan J L Kaspers, Mats O Karlsson, Lena E Friberg
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clinical pharmacokinetics 63 (2) (2023)
Maddalena Centanni, Mirjam E van de Velde, Aniek Uittenboogaard, Gertjan J L Kaspers, Mats O Karlsson, Lena E Friberg
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clinical pharmacokinetics 63 (2) (2023)
Ana-Marija Grisic, Wenyuan Xiong, Lénaïg Tanneau, Siv Jonsson, Lena E Friberg, Mats O Karlsson, Haiqing Dai, Jenny Zheng, Pascal Girard, Akash Khandelwal
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Sreenath M Krishnan, Lena E Friberg
Bayesian forecasting of tumor size metrics and overall survival. CPT: pharmacometrics & systems pharmacology (2022)
Sammy Frenk, Elizabeth Temkin, Mor N Lurie-Weinberger, Alona Keren-Paz, Reut Rov, Nadya Rakovitsky, Liat Wullfhart, Amir Nutman, George L Daikos, Anna Skiada, Emanuele Durante-Mangoni, Yael Dishon Benattar, Roni Bitterman, Dafna Yahav, Vered Daitch, Mariano Bernardo, Domenico Iossa, Oren Zusman, Lena E Friberg, Johan W Mouton, Ursula Theuretzbacher, Leonard Leibovici, Yuval Geffen, Rina Gershon, Mical Paul, Yehuda Carmeli
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. The Journal of antimicrobial chemotherapy 77 (4) (2022)
Karen Rowland Yeo, Stefanie Hennig, Sriram Krishnaswami, Natasha Strydom, Vivaswath S Ayyar, Jonathan L French, Vikram Sinha, Eric Sobie, Ping Zhao, Lena E Friberg, France Mentré
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision. CPT: pharmacometrics & systems pharmacology 10 (7) (2022)
Iris K Minichmayr, Suzanne Kappetein, Margreke J E Brill, Lena E Friberg
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings. Antibiotics (Basel, Switzerland) 11 (8) (2022)
Chenyan Zhao, Anna Chirkova, Staffan Rosenborg, Rodrigo Palma Villar, Johan Lindberg, Sven N Hobbie, Lena E Friberg
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. The Journal of antimicrobial chemotherapy 77 (10) (2022)
Maddalena Centanni, Abel Thijs, Ingrid Desar, Mats O Karlsson, Lena E Friberg
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors. Clinical and translational science (2022)
Robin J Svensson, Qing-Xi Ooi, Lena E Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López-Lázaro, Emma Hansson
Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity. CPT: pharmacometrics & systems pharmacology (2022)
Sreenath M Krishnan, Sofiene S Laarif, Brendan C Bender, Angelica L Quartino, Lena E Friberg
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel. CPT: pharmacometrics & systems pharmacology 10 (5) (2021)
Maddalena Centanni, Sreenath M Krishnan, Lena E Friberg
Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Ida Netterberg, Mats O Karlsson, Leon W M M Terstappen, Miriam Koopman, Cornelis J A Punt, Lena E Friberg
Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (18) (2020)
Ida Netterberg, Mats O Karlson, Elisabet I Nielsen, Angelica L Quartino, Henrik Lindman, Lena E Friberg
The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. British journal of clinical pharmacology 84 (3) (2018)
Ida Netterberg, Elisabet I Nielsen, Lena E Friberg, Mats O Karlson
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. Cancer chemotherapy and pharmacology 80 (2) (2017)
Muhammad W Sadiq, Elisabet I Nielsen, Dalia Khachman, Jean-Marie Conil, Bernard Georges, Georges Houin, Celine M Laffont, Mats O Karlsson, Lena E Friberg
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of pharmacokinetics and pharmacodynamics 44 (2) (2016)

Lena E Friberg.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lena E Friberg